JPWO2020084115A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084115A5 JPWO2020084115A5 JP2021523064A JP2021523064A JPWO2020084115A5 JP WO2020084115 A5 JPWO2020084115 A5 JP WO2020084115A5 JP 2021523064 A JP2021523064 A JP 2021523064A JP 2021523064 A JP2021523064 A JP 2021523064A JP WO2020084115 A5 JPWO2020084115 A5 JP WO2020084115A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkylene
- substituted
- substituents
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims description 68
- 239000003814 drug Substances 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 55
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 125000000732 arylene group Chemical group 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 229910052717 sulfur Chemical group 0.000 claims description 13
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 48
- 102000036639 antigens Human genes 0.000 claims 48
- 108091007433 antigens Proteins 0.000 claims 48
- 239000012634 fragment Substances 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000000562 conjugate Substances 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 12
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 229960000575 trastuzumab Drugs 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229960000455 brentuximab vedotin Drugs 0.000 claims 4
- 229960000578 gemtuzumab Drugs 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 241000282414 Homo sapiens Species 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 229960000446 abciximab Drugs 0.000 claims 3
- 229960000548 alemtuzumab Drugs 0.000 claims 3
- 229960003852 atezolizumab Drugs 0.000 claims 3
- 229950002916 avelumab Drugs 0.000 claims 3
- 229960004669 basiliximab Drugs 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229960002806 daclizumab Drugs 0.000 claims 3
- 229960002204 daratumumab Drugs 0.000 claims 3
- 229960001251 denosumab Drugs 0.000 claims 3
- 229960004497 dinutuximab Drugs 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 229960004137 elotuzumab Drugs 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 229960005386 ipilimumab Drugs 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 229950000518 labetuzumab Drugs 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 229960000513 necitumumab Drugs 0.000 claims 3
- 229950010203 nimotuzumab Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960003347 obinutuzumab Drugs 0.000 claims 3
- 229960002450 ofatumumab Drugs 0.000 claims 3
- 229950008516 olaratumab Drugs 0.000 claims 3
- 229960000470 omalizumab Drugs 0.000 claims 3
- 229960000402 palivizumab Drugs 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 229960001972 panitumumab Drugs 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 229960002633 ramucirumab Drugs 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229960003323 siltuximab Drugs 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- -1 2-pyridylmethyl- Chemical group 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 229960000419 catumaxomab Drugs 0.000 claims 2
- 229950002756 depatuxizumab Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006301 indolyl methyl group Chemical group 0.000 claims 2
- 229950001813 laprituximab Drugs 0.000 claims 2
- 229950007243 mirvetuximab Drugs 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 229950002138 naratuximab Drugs 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229950007463 rovalpituzumab Drugs 0.000 claims 2
- 229950001460 sacituzumab Drugs 0.000 claims 2
- 125000004149 thio group Chemical group *S* 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229950000918 glembatumumab Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229950006289 indusatumab Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382759.1 | 2018-10-25 | ||
| EP18382759 | 2018-10-25 | ||
| PCT/EP2019/079188 WO2020084115A1 (en) | 2018-10-25 | 2019-10-25 | Antibody drug conjugates comprising ecteinascidin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512830A JP2022512830A (ja) | 2022-02-07 |
| JPWO2020084115A5 true JPWO2020084115A5 (es) | 2024-03-21 |
Family
ID=64426824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523064A Pending JP2022512830A (ja) | 2018-10-25 | 2019-10-25 | エクテナサイジン誘導体を含む薬物抗体複合体 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20230012681A1 (es) |
| EP (1) | EP3870234B1 (es) |
| JP (1) | JP2022512830A (es) |
| KR (1) | KR20210086669A (es) |
| CN (1) | CN113226377B (es) |
| AR (1) | AR117657A1 (es) |
| AU (1) | AU2019368687A1 (es) |
| BR (1) | BR112021007718A2 (es) |
| CA (1) | CA3117268C (es) |
| CL (1) | CL2021001039A1 (es) |
| CO (1) | CO2021006838A2 (es) |
| DK (1) | DK3870234T3 (es) |
| EA (1) | EA202191131A1 (es) |
| EC (1) | ECSP21035414A (es) |
| ES (1) | ES2939494T3 (es) |
| FI (1) | FI3870234T3 (es) |
| HR (1) | HRP20230275T1 (es) |
| HU (1) | HUE061606T2 (es) |
| IL (1) | IL282577B2 (es) |
| JO (1) | JOP20210083A1 (es) |
| LT (1) | LT3870234T (es) |
| MA (1) | MA59661B1 (es) |
| MD (1) | MD3870234T2 (es) |
| MX (1) | MX2021004746A (es) |
| PH (1) | PH12021550930A1 (es) |
| PL (1) | PL3870234T3 (es) |
| PT (1) | PT3870234T (es) |
| RS (1) | RS64068B1 (es) |
| SG (1) | SG11202104154WA (es) |
| SI (1) | SI3870234T1 (es) |
| TW (1) | TWI824043B (es) |
| WO (1) | WO2020084115A1 (es) |
| ZA (1) | ZA202103478B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190254A1 (ar) * | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| CA3218171A1 (en) * | 2021-05-19 | 2022-11-24 | Carmen KAHATT | Dosage regimens for ecubectedin |
| KR102625740B1 (ko) * | 2021-07-15 | 2024-01-17 | 주식회사 새한비엠 | 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| AR035842A1 (es) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
| PL1928503T3 (pl) | 2005-08-24 | 2012-12-31 | Immunogen Inc | Sposób wytwarzania koniugatów majtazynoid-przeciwciało |
| JOP20190254A1 (ar) * | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
-
2019
- 2019-10-23 TW TW108138205A patent/TWI824043B/zh active
- 2019-10-24 AR ARP190103069A patent/AR117657A1/es unknown
- 2019-10-25 PT PT197905508T patent/PT3870234T/pt unknown
- 2019-10-25 MD MDE20210819T patent/MD3870234T2/ro unknown
- 2019-10-25 KR KR1020217015900A patent/KR20210086669A/ko unknown
- 2019-10-25 SI SI201930466T patent/SI3870234T1/sl unknown
- 2019-10-25 JP JP2021523064A patent/JP2022512830A/ja active Pending
- 2019-10-25 EA EA202191131A patent/EA202191131A1/ru unknown
- 2019-10-25 PL PL19790550.8T patent/PL3870234T3/pl unknown
- 2019-10-25 IL IL282577A patent/IL282577B2/en unknown
- 2019-10-25 EP EP19790550.8A patent/EP3870234B1/en active Active
- 2019-10-25 WO PCT/EP2019/079188 patent/WO2020084115A1/en active Search and Examination
- 2019-10-25 HU HUE19790550A patent/HUE061606T2/hu unknown
- 2019-10-25 DK DK19790550.8T patent/DK3870234T3/da active
- 2019-10-25 MA MA59661A patent/MA59661B1/fr unknown
- 2019-10-25 HR HRP20230275TT patent/HRP20230275T1/hr unknown
- 2019-10-25 ES ES19790550T patent/ES2939494T3/es active Active
- 2019-10-25 FI FIEP19790550.8T patent/FI3870234T3/fi active
- 2019-10-25 US US17/288,567 patent/US20230012681A1/en active Pending
- 2019-10-25 SG SG11202104154WA patent/SG11202104154WA/en unknown
- 2019-10-25 BR BR112021007718-9A patent/BR112021007718A2/pt unknown
- 2019-10-25 AU AU2019368687A patent/AU2019368687A1/en active Pending
- 2019-10-25 LT LTEPPCT/EP2019/079188T patent/LT3870234T/lt unknown
- 2019-10-25 CA CA3117268A patent/CA3117268C/en active Active
- 2019-10-25 JO JOP/2021/0083A patent/JOP20210083A1/ar unknown
- 2019-10-25 RS RS20230219A patent/RS64068B1/sr unknown
- 2019-10-25 MX MX2021004746A patent/MX2021004746A/es unknown
- 2019-10-25 CN CN201980084790.7A patent/CN113226377B/zh active Active
-
2021
- 2021-04-22 CL CL2021001039A patent/CL2021001039A1/es unknown
- 2021-04-23 PH PH12021550930A patent/PH12021550930A1/en unknown
- 2021-05-20 EC ECSENADI202135414A patent/ECSP21035414A/es unknown
- 2021-05-21 ZA ZA2021/03478A patent/ZA202103478B/en unknown
- 2021-05-24 CO CONC2021/0006838A patent/CO2021006838A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109912683B (zh) | 一种细胞毒素分子、偶联物及其制备方法和应用 | |
| AU2016282723B2 (en) | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups | |
| CN107921144B (zh) | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 | |
| KR102419766B1 (ko) | 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc | |
| BR112020020466A2 (pt) | Conjugados de peptídeo de camptotecina | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| HRP20230275T1 (hr) | Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina | |
| EP3210627A1 (en) | Conjugates of cell binding molecules with cytotoxic agents | |
| CA3105541A1 (en) | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates | |
| CA3016172A1 (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| KR20140139480A (ko) | 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법 | |
| RU2015156499A (ru) | Конъюгаты антитела с лекарственным средством | |
| CA3181660A1 (en) | Conjugates of a cell-binding molecule with camptothecin analogs | |
| PL172824B1 (pl) | Nowe koniugaty tioeterowe PL PL PL PL PL | |
| JP2012522513A5 (es) | ||
| JP2018524313A (ja) | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体 | |
| AU2019452577B2 (en) | Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor | |
| JPWO2020252294A5 (es) | ||
| JP2023520930A (ja) | 電荷多様性リンカー | |
| JP2019537622A (ja) | 非線状自壊性リンカーおよびそのコンジュゲート | |
| JP2024521629A (ja) | 抗体薬物コンジュゲート、及びその調製方法及びその使用 | |
| CN115515642A (zh) | 抗cd56抗体-药物偶联物及其在治疗中的用途 | |
| JPWO2020200880A5 (es) | ||
| JPWO2020084115A5 (es) | ||
| JP2019507126A5 (es) |